On the stock market since 2014, it operates in the world of health and science. It has 50 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
If every debt were paid off today, $6.8M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $6.8M in the vault; even if every debt were paid off, $6.8M would remain.
It pays out $0.50 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 2/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, ELVAY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ELVAY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.